Skip to main content
Clinical Trials/NCT04702373
NCT04702373
Active, not recruiting
Phase 3

Training in Exercise Activities and Motion for Growth: A Randomized Clinical Trial

Carelon Research10 sites in 2 countries144 target enrollmentFebruary 23, 2021

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Congenital Heart Disease
Sponsor
Carelon Research
Enrollment
144
Locations
10
Primary Endpoint
weight-for-age z-score
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

This is a Phase III randomized controlled trial of a passive ROM exercise program that will be performed in infants with HLHS and other single right ventricle anomalies following the Norwood procedure at PHN and Auxiliary Centers.

Detailed Description

Growth is often impaired in infants with congenital heart disease (CHD). Nutritional interventions, drug therapy and surgical palliation have had varying degrees of success in enhancing growth. Passive ROM has improved somatic growth in preterm infants and has been demonstrated in a previous Pediatric Heart Network (PHN) to be safe and feasible in neonate's post-Norwood procedure. Improved growth may also favorably impact neurodevelopment, behavioral state, and time to hospital discharge. This study's objectives are to evaluate growth in infants with hypoplastic left heart syndrome (HLHS) or other single right ventricle (RV) anomalies after the Norwood procedure who are randomized to a passive range of motion (ROM) exercise program vs. standard of care.

Registry
clinicaltrials.gov
Start Date
February 23, 2021
End Date
December 30, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Carelon Research
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • hospitalized infants with HLHS or other single RV anomalies
  • \>=37 weeks gestation
  • \<=35 days of age
  • planned Norwood procedure (or hybrid leading to Norwood within 35 days)
  • parent or guardian willing to comply with protocol and provide written informed consent

Exclusion Criteria

  • birthweight \<3rd percentile for gestational age
  • chromosomal or recognizable phenotypic syndrome of non-cardiac congenital abnormalities associated with growth failure (for example Trisomy, Noonan, or Turner syndromes)
  • non-cardiac diagnosis associated with growth failures
  • listed for cardiac transplant
  • anticipated discharge within 14 days of screening

Outcomes

Primary Outcomes

weight-for-age z-score

Time Frame: 4 months of age or superior cavopulmonary connection (SCPC) evaluation clinic visit, whichever comes first

weight-for-age z-score

Secondary Outcomes

  • length-for-age z-score(4 months of age or superior cavopulmonary connection (SCPC) evaluation clinic visit, whichever comes first)
  • head circumference-for-age z-score(4 months of age or superior cavopulmonary connection (SCPC) evaluation clinic visit, whichever comes first)
  • Neonatal Intensive Care Unit (NICU) Network Neurobehavioral Scale (NNNS) subdomain scores(Post-operative day 21 or discharge, whichever comes first)
  • DXA(4 months of age or superior cavopulmonary connection (SCPC) evaluation clinic visit, whichever comes first)
  • Tests of Infant Motor Performance (TIMP)(4 months of age or superior cavopulmonary connection (SCPC) evaluation clinic visit, whichever comes first)

Study Sites (10)

Loading locations...

Similar Trials